Castle Biosciences

244 articles with Castle Biosciences

• Study Shows Castle Biosciences’ Cutaneous Melanoma Gene Expression Profile Test Improves Identification Of High Risk Disease In Tumors Of Intermediate T2/T3 Thickness

  6/2/2015

• Castle Biosciences Expands Sales Force And Appoints Patrick Hall As Executive Director Of Medical Affairs, Promotes Robert W. Cook To Executive Director, R&D

  5/28/2015

• Castle Biosciences Hires Vice President Of Marketing

  4/21/2015

• Castle Biosciences Secures $6 Million Credit Facility From Silicon Valley Bank

  4/14/2015

• Study Shows Castle Biosciences’ Noninvasive Skin Melanoma Gene Test Improves Accuracy Of Sentinel Lymph Node Biopsy In Predicting Metastasis

  3/5/2015

• Castle Biosciences Announces New Director Appointment And CFO Hire

  2/24/2015

• Study Of Castle Biosciences’ Skin Melanoma Gene Test Published In Clinical Cancer Research

  1/6/2015

• Castle Biosciences’ Multi-Analyte Test Successfully Identifies Esophageal Cancer Patients Who Are Extremely Resistant To Standard Treatment Of Chemoradiation Therapy

  10/23/2014

• Castle Biosciences Snags $11.8 Million Financing

  8/13/2014

• Study Shows Castle Biosciences’ Gene Expression Profile Test Successfully Identified High Risk Disease In A Cohort Of 217 Melanoma Patients Who Underwent Sentinel Lymph Node Biopsy

  6/2/2014

• Castle Biosciences' Esophageal Cancer Test Accurately Predicts Pre-Surgical Treatment Response

  6/2/2014

• Castle Biosciences' Melanoma Gene Expression Profile Test To Be Subject Of Presentation At American Society of Clinical Oncology Annual Meeting

  5/15/2014

• Castle Biosciences' Esophageal Cancer Test Identifies Patients Who Are Resistant To Standard Pre-Surgical Chemoradiation Therapy

  5/6/2014

• Castle Biosciences' Mesothelioma Molecular Test Accurately Stratifies Survival Risk Under Surgical And Non-Surgical Treatment Plans

  4/29/2014

• Castle Biosciences Announces Data Demonstrating Ability To Identify Esophageal Cancer Patients Resistant To Standard Pre-Surgical Treatment Of Chemotherapy And Radiation

  1/16/2014

• Castle Biosciences Launches Tissue Repository for Eye Cancer Patients

  9/30/2013

• Castle Biosciences Genetic Test Highly Accurate in Differentiating Thymomas From Thymic Carcinoma Tumors

  9/25/2013

• Castle Biosciences Release: Gene Test Identifies Non-Metastatic Melanoma Patients at High Risk of Recurrence

  8/5/2013

• Castle Biosciences Release: New Website Dedicated to Patients With Thymic Cancer

  7/30/2013

• Castle Biosciences Release: Gene Test Highly Accurate in Predicting Metastasis in Patients With Thymoma

  7/25/2013